The government alleges that BioReference submitted claims to federal healthcare programs for blood tests that were not ordered by a patient's provider.

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.

The QuickFinder COVID-19/Flu Antigen Self-Test and the QuickFinder COVID-19/Flu Antigen Pro Test detect SARS-CoV-2, influenza A, and influenza B in swab specimens and provide results within 15 minutes ...

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

NEW YORK – A University of Michigan lab has developed a blood-based test to detect recurrence of human papilloma virus-positive head and neck cancer sooner than standard-of-care imaging and clinical ...

The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.

OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

Highlights from the first day included updates from several firms about their China businesses and M&A strategies.

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...

The Dublin-based firm said that it will use the money for development for its rapid test to aid the diagnosis and treatment of sepsis.